Comparative Pharmacology
Head-to-head clinical analysis: MOTPOLY XR versus PREFRIN A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTPOLY XR versus PREFRIN A.
MOTPOLY XR vs PREFRIN-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MOTPOLY XR is a combination of an opioid agonist (morphine) and an opioid antagonist (naltrexone). The extended-release formulation allows for sequential release: an initial morphine dose followed by naltrexone, which mitigates opioid-induced adverse effects by antagonizing mu-opioid receptors in the gastrointestinal tract without affecting central analgesia.
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
Adults: 10 mg orally once daily, with or without food.
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
Terminal half-life 12–15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Renal: ~60% unchanged; biliary/fecal: ~25% as metabolites; <5% unchanged in feces.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Category C
Category C
Decongestant/Antihistamine Combination
Ophthalmic Decongestant/Antihistamine Combination